<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405208</url>
  </required_header>
  <id_info>
    <org_study_id>CP-HRA-002</org_study_id>
    <nct_id>NCT02405208</nct_id>
  </id_info>
  <brief_title>A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing</brief_title>
  <acronym>CHRA</acronym>
  <official_title>A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integra LifeSciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multi-center, nonrandomized, uncontrolled, unblinded, prospective&#xD;
      clinical outcomes investigation to evaluate the short, mid and long term performance of the&#xD;
      PyroTITAN™ HRA Shoulder prosthesis humeral replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a multi-center, nonrandomized, uncontrolled, unblinded, prospective&#xD;
      clinical outcomes investigation to evaluate the short, mid and long term performance of the&#xD;
      PyroTITAN™ HRA Shoulder prosthesis humeral replacement. The PyroTITAN™ HRA Shoulder&#xD;
      prosthesis device configuration will include humeral resurfacing CAP without cement. Patients&#xD;
      will be selected for recruitment into the study based upon the normally accepted criteria for&#xD;
      primary shoulder resurfacing arthroplasty.&#xD;
&#xD;
      The investigation will be conducted by up to 10 International surgeons experienced in HRA.&#xD;
      387 subjects with PyroTITAN™ HRA Shoulder prosthesis arthroplasties will be implanted and&#xD;
      followed for 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ASES</measure>
    <time_frame>2 years</time_frame>
    <description>The ASES Shoulder Score is a functional outcome tool that has been validated for various shoulder conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The WOOS score</measure>
    <time_frame>2 years</time_frame>
    <description>The WOOS Score is a quality of life questionnaire that has been validated for various shoulder conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>2 years</time_frame>
    <description>The Visual Analog Scale (VAS) form assesses pain, shoulder pain and satisfaction as it relates to the effected shoulder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ 5D</measure>
    <time_frame>2 years</time_frame>
    <description>The EQ-5D Questionnaire consists of information pertaining to the current health status of the patient at the time of evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Constant Score</measure>
    <time_frame>2 years</time_frame>
    <description>The Constant Score is a commonly used score of shoulder function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in joint range of motion</measure>
    <time_frame>2 years</time_frame>
    <description>Assesses the range of motion in the shoulder</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No evidence of device failure on X-rays</measure>
    <time_frame>2 years</time_frame>
    <description>true anterior-posterior in the scapular plane, internal and external rotation, axial lateral and an axillary lateral view.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>to assess the safety of the device</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">142</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Primary cohort</arm_group_label>
    <description>Primary cohort will receive the PyroTITAN HRA device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PyroTITAN HRA</intervention_name>
    <description>Humeral resurfacing using the PyroTITAN HRA device</description>
    <arm_group_label>Primary cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who require humeral head resurfacing arthroplasty.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients selected for inclusion will present for primary shoulder surface replacement&#xD;
             or arthroplasty with any of the following diagnoses:&#xD;
&#xD;
               -  Osteoarthritis&#xD;
&#xD;
               -  Rheumatoid / Inflammatory Arthritis&#xD;
&#xD;
               -  Post-traumatic arthritis.&#xD;
&#xD;
               -  Focal and large (Hill-Sachs) osteochondral defects.&#xD;
&#xD;
          2. Subject is able to or capable of providing consent to participate in the clinical&#xD;
             investigation.&#xD;
&#xD;
          3. Subject agrees to comply with this protocol, including participating in required&#xD;
             follow-up visits at the investigations site and completing study questionnaires.&#xD;
&#xD;
          4. Subject is at least 21 years of age and skeletally mature at the time of surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have destruction of the proximal humerus to preclude rigid fixation of the humeral&#xD;
             component.&#xD;
&#xD;
          2. Insufficient bone quality as determined by intra-operative evaluation.&#xD;
&#xD;
          3. Have arthritis with defective rotator cuff.&#xD;
&#xD;
          4. Have had a failed rotator cuff surgery.&#xD;
&#xD;
          5. Have loss of musculature, neuromuscular compromise or vascular deficiency in the&#xD;
             affected limb rendering the procedure unjustified.&#xD;
&#xD;
          6. Have evidence of active infection.&#xD;
&#xD;
          7. Present with a condition of neuromuscular compromise of the shoulder (e.g.,&#xD;
             neuropathic joints or brachioplexis injury with a flail shoulder joint).&#xD;
&#xD;
          8. Are unwilling or unable to comply with a rehabilitation program or would fail to&#xD;
             return for the postoperative follow-up visits prescribed by the protocol.&#xD;
&#xD;
          9. Are skeletally immature.&#xD;
&#xD;
         10. Have a known allergic reaction to pyrocarbon.&#xD;
&#xD;
         11. Have other conditions such as central nervous system disturbances, alcohol or drug&#xD;
             addiction, etc. that may make effective evaluation of the joint replacement difficult&#xD;
             or impossible.&#xD;
&#xD;
         12. Are currently participating in another clinical study.&#xD;
&#xD;
         13. Have known, active metastatic or neoplastic disease.&#xD;
&#xD;
         14. Are taking &gt; 10mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3&#xD;
             months prior to surgery.&#xD;
&#xD;
         15. Are under 21 years of age or over 75.&#xD;
&#xD;
             .&#xD;
&#xD;
         16. Require glenoid replacement (Glenoid Classification).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Tummon</last_name>
    <role>Study Director</role>
    <affiliation>Integra LifeSciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brisbane Hand &amp; Upper Limb Clinic</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Nices</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wrightington Hospital</name>
      <address>
        <city>Wigan</city>
        <state>Wrightington</state>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

